Skip to main content
MEDS
NASDAQ Trade & Services

DataMeds AI Inks LOI for Transformative Reverse Merger with EOS, Scilex, Datavault, and HBA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Neutral
Importance info
9
Price
$3.17
Mkt Cap
$8.317M
52W Low
$2.485
52W High
$97.5
52W Position info
28% above low
Off High info
97% below high
Rel. Volume
Market data snapshot near publication time

MEDS sits 28% above its 52-week low of $2.485.

Summary

DataMeds AI signed a non-binding LOI for a reverse merger that would give EOS, Scilex, Datavault, and HBA ~84.6% ownership, leaving public shareholders with ~10.4%. The deal includes IP acquisitions, license expansion, and a controlling stake in Tollo Health, alongside immediate management changes and a $2M minimum investment.


Key Events · M&A and Partnerships · MEDS

  • Transformative LOI Signed

    On July 29, 2026, DataMeds AI entered an Amended and Restated LOI to acquire QLPM IP from EOS and Scilex, expand its Datavault license, and acquire a controlling interest in Tollo Health from HBA, in exchange for common stock.

  • Post-Close Ownership Shift

    Upon closing, EOS, Scilex, Datavault, and HBA would collectively own ~84.6% of MEDS common stock, with existing public shareholders diluted to ~10.4% on a fully diluted basis, subject to adjustments.

  • Immediate Leadership Changes

    To facilitate the transaction, Gerald Commissiong of Fortitude Advisors has been appointed Interim Co-CEO alongside current President Prashant Patel, and Dan Hirsch has been hired as Interim VP of Finance.

  • Minimum $2M Investment and ATM

    The LOI requires a concurrent minimum $2 million investment from Dawson James Investors and an At-The-Market facility filing within 14 days to address outstanding liabilities.


Analysis · MEDS · Trade & Services

DataMeds AI has entered into an Amended and Restated Letter of Intent that would fundamentally reshape the company. The proposed transaction brings in QLPM drone-delivery IP, expands a blockchain healthcare license, and acquires Tollo Health—with the selling parties taking roughly 84.6% ownership post-close. Existing public shareholders would be diluted to approximately 10.4%. The LOI also triggers immediate leadership changes, a $2 million minimum investment, and an ATM filing. While still non-binding and subject to due diligence, financing, and shareholder approval, the proposed terms represent a near-total change of control and a pivot to a new business focus. The exclusivity period runs through September 30, 2026, locking the company into negotiations. If consummated, this would be a thesis-altering event for current MEDS holders.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MEDS was trading at $3.17 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $2.48 to $97.50. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MEDS - Latest Insights

MEDS
Nov 16, 2026, 8:42 AM EST
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.7001
Real-time Price: $1.03 info
Change: +$0.3297 (+47%) info
Market Cap: $4.161M info
MEDS
Nov 16, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $1.03 info
Change: +$0.3198 (+45%) info
Market Cap: $4.161M info
MEDS
Nov 13, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7251
Real-time Price: $1.03 info
Change: +$0.3047 (+42%) info
Market Cap: $4.161M info
MEDS
Nov 13, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7499
Real-time Price: $1.03 info
Change: +$0.2799 (+37%) info
Market Cap: $4.161M info
MEDS
Nov 13, 2026, 10:20 AM EST
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.8795
Real-time Price: $1.03 info
Change: +$0.1503 (+17%) info
Market Cap: $4.161M info